What is Lifecore Biomedical, Inc.'s D&A?

Lifecore Biomedical, Inc. (LFCR) reported D&A of $1.98M in Q3 2025.

How has Lifecore Biomedical, Inc.'s D&A changed year-over-year?

Lifecore Biomedical, Inc.'s D&A decreased by 3.1% year-over-year, from $2.04M to $1.98M.

What is the long-term trend for Lifecore Biomedical, Inc.'s D&A?

Over 3 years (2022 to 2025), Lifecore Biomedical, Inc.'s D&A has grown at a -23.6% compound annual growth rate (CAGR), from $18M to $8.03M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Lifecore Biomedical, Inc. LFCR D&A

Discontinued — last reported Q2 '26

D&A at other companies

Baxter InternationalBAX

$237M-4.0%

ADMA BiologicsADMA

$1.8M-5.3%

Medpace Holdings, Inc.MEDP

$155K-34.3%

Charles River LaboratoriesCRL

$67.15M-44.2%

Labcorp HoldingsLH

$75.6M+8.6%

West Pharmaceutical ServicesWST

——

Segments

By segment

See full

Reportable Segment$2.31M—

Other financials

Income statement

See full

Revenue$23.2M-36.4%

Gross profit$4.5M-68.1%

Operating income-$4.7M—

Net income-$15.0M-1,206%

EPS (diluted)-$0.43-1,333%

Balance sheet

See full

Cash & equivalents$20.8M+152%

Total debt$156.9M+1,310%

Total equity-$28.4M-2,229%

Total assets$225.5M-5.8%

Cash flow

See full

Operating cash flow$4.7M—

CapEx$1.1M-46.7%

Free cash flow$3.6M—

Valuation

See full

Market cap$196.92M-37.3%

Enterprise value$333.06M+6.3%

P/S1.6×+0.5×

Profitability

See full

Gross margin31.3%-1.4pp

Operating margin-14.5%-2.2pp

Net margin-30%—

FCF margin-36.4%—

Returns & leverage

See full

Return on equity-612.1%—

Debt / equity8.3×-1.5×

Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed November 6, 2025, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s D&A?: Lifecore Biomedical, Inc. (LFCR) reported D&A of $1.98M in Q3 2025.
How has Lifecore Biomedical, Inc.'s D&A changed year-over-year?: Lifecore Biomedical, Inc.'s D&A decreased by 3.1% year-over-year, from $2.04M to $1.98M.
What is the long-term trend for Lifecore Biomedical, Inc.'s D&A?: Over 3 years (2022 to 2025), Lifecore Biomedical, Inc.'s D&A has grown at a -23.6% compound annual growth rate (CAGR), from $18M to $8.03M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.